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Pain is a complex warning system activated
in response to potential or apparent dan-
ger and the absence of pain is detrimental.
Nociceptive pain is high-threshold pain
activated in the presence of intense stimuli,
such as contact with a burning object, and
is a protective system essential for detec-
tion of noxious stimuli. Inflammatory
pain, caused by immune system activation
in response to tissue injury or infection,
is also protective, as it discourages phys-
ical contact with the damaged area and
assists healing (Woolf, 2010). In contrast,
neuropathic pain emanating from disease
or damage to the somatosensory system, is
somewhat unique in that it is not protec-
tive, but rather pathological. Neuropathic
pain encompasses a series of heteroge-
neous conditions with some similar clin-
ical manifestations. Peripheral examples
include traumatic nerve injury, diabetic
peripheral neuropathy and chemotherapy-
induced peripheral neuropathy, whilst
multiple sclerosis is an example of a
disease which can result in centrally
derived neuropathic pain. These condi-
tions are characterized by a low-threshold
chronic pain emanating from aberrant
peripheral and central neuronal sensiti-
zation. Symptoms include paraesthesia,
spontaneous ongoing pain, and evoked
pain (e.g., hyperalgesia and allodynia).
Recent studies investigating neuropathic
pain have demonstrated significant asso-
ciated immune system activation and a
fundamental role for cytokine signaling
(Austin and Moalem-Taylor, 2010).
In this Opinion Article, we briefly sum-
marize the progress made on research
of cytokine involvement in neuropathic
pain states and suggest that targeting key
cytokines may prove useful in the devel-
opment of new immune-therapeutics.
However, further studies are required to
determine which cytokine is the appro-
priate target for specific neuropathic pain
conditions.
CYTOKINE EXPRESSION AFTER NERVE
INJURY
Dysregulation of cytokines has been impli-
cated in a variety of neuropathic pain con-
ditions in both humans and animals. For
example, differential expression of blood
and cerebrospinal fluid cytokines has been
demonstrated in patients with painful
neuropathies. Compared to healthy con-
trols, these patients show higher lev-
els of proinflammatory cytokines [e.g.,
interleukin (IL)-1β and tumor necrosis
factor-α (TNFα)], and lower levels of
anti-inflammatory cytokines (e.g., IL-10)
(Uceyler et al., 2007; Backonja et al.,
2008). Animal models of peripheral nerve
injury, such as chronic constriction injury
(CCI) of the sciatic nerve, demonstrate
extensive infiltration into the peripheral
nervous system by cytokine producing
immune cells (Moalem et al., 2004; Hu
et al., 2007). Nerve injury increases expres-
sion and secretion of proinflammatory
cytokines, including TNFα, IL-1β, IL-6,
and interferon-γ, all of which are required
for the development of pain hypersensitiv-
ity (Murphy et al., 1995; Costigan et al.,
2009). Injury to neurons of the central
nervous system (CNS) also initiates an
immune response involving cytokine sig-
naling (Guptarak et al., 2013).
In cases of peripheral nerve injury, the
local inflammatory response is followed
by a proximal response in both the dor-
sal root ganglion (DRG) and the spinal
cord. Activated glial cells within the dor-
sal horn are critically involved in trans-
mission of pain and are pivotal to the
maintenance of chronic neuropathic pain
(Austin and Moalem-Taylor, 2010). Both
the major types of glia within the CNS
(astrocytes and microglia) are particu-
larly sensitive to activation following nerve
injury (Mika et al., 2013). Furthermore,
glia secrete cytokines and are likely to be
the major source of central proinflam-
matory cytokines TNFα, IL-1β, and IL-6
(Whitehead et al., 2010). Classically char-
acterized as messengers of the immune
system, cytokines can act upon many dif-
ferent cell types, including neurons. For
example IL-1β (Binshtok et al., 2008),
TNFα (Jin and Gereau, 2006), and IL-17A
(Richter et al., 2012) all can directly acti-
vate nociceptors and induce pain hyper-
sensitivity.
Shortly after CCI, mRNA coding for
the cytokine TNFα is rapidly elevated in
the sciatic nerve (within hours of injury)
and subsequently in the DRG (1–3 days
following injury) (Sacerdote et al., 2008).
TNFα alters the excitability of neurons
and promotes continued inflammation
(Sorkin et al., 1997). For at least 2 weeks,
TNFα and its receptor TNFR1, display ele-
vated expression in the ipsilateral and con-
tralateral DRG of nerve-injured animals
(Dubovy et al., 2006). Within the DRG
and spinal cord, signaling via TNFR1,
results in activation of NF-κB pathway fol-
lowed by up-regulation of IL-6 (Lee et al.,
2009). Bilateral elevated levels of IL-6 are
observed in the DRG following unilateral
CCI and furthermore in distant cervical
DRG, suggesting a wider neuroinflamma-
tory response (Dubovy et al., 2013). IL-
1β precipitates pain hypersensitivity when
administered to the sciatic nerve (Zelenka
et al., 2005) or intrathecally (Sung et al.,
2004). In vitro exposure to IL-1β leads to
increased excitability in medium and small
DRG neurons (Stemkowski and Smith,
2012). IL-1β also acts in higher CNS
regions whereby supraspinal changes in
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IL-1β expression alter over time in the
brainstem, thalamus and prefrontal cortex
following sciatic nerve injury (Apkarian
et al., 2006). Furthermore, IL-1β is ele-
vated in the contralateral hippocampus of
rats with CCI and spinal nerve ligation
(SNL) (del Rey et al., 2011).
THERAPEUTICS TARGETING
PROINFLAMMATORY CYTOKINES
Numerous studies have demonstrated that
antagonism of proinflammatory cytokine
signaling attenuates neuronal hypersensi-
tivity and inflammation associated with
nerve injury. For example, intrathecal
injection of both IL-1β and TNFα antago-
nists alleviated pain induced by gp120 acti-
vated spinal injury (Milligan et al., 2001).
Similarly, intrathecal administration of an
IL-6 neutralizing antibody significantly
reduced gp120-induced mechanical allo-
dynia and down-regulated the expres-
sion of IL-1β and TNFα within the
CNS (Schoeniger-Skinner et al., 2007).
Biologics which target the activity of spe-
cific proinflammatory cytokines have been
and continue to be developed. A com-
mon theme associated with their clinical
use is that they are generally well-tolerated
(Dinarello et al., 2012).
TNFα INHIBITORS
TNFα inhibitors are demonstrated to sig-
nificantly reduce mechanical and ther-
mal pain hypersensitivity associated with
peripheral nerve injury (Iwatsuki et al.,
2013). There are several TNFα inhibitors
which have been developed, including the
humanized monoclonal antibody inflix-
imab and the receptor fusion protein etan-
ercept. These and other TNFα inhibitors
are currently approved for clinical use to
treat a range of immune disorders includ-
ing rheumatoid arthritis, chrohn’s dis-
ease, and psoriasis. Infliximab was tested
in a human clinical trial for the treat-
ment of pain associated with disc her-
niation induced sciatica. The drug failed
to show a significant reduction in pain
across the entire treatment group, but
patients with L3–L4 and L4–L5 disc her-
niation appeared to benefit (Korhonen
et al., 2006). Etanercept was tested in
humans suffering from sciatica and shown
to have significant benefits in a pilot study
(Genevay et al., 2004). Similarly in another
small trial, epidural administration of
etanercept was effective in reducing pain
associated with spinal stenosis (Ohtori
et al., 2012a). However, results from a
randomized, double blind, placebo con-
trolled trial for the treatment of radicu-
lar or discogenic back pain indicated that
etanercept did not demonstrate any signif-
icant benefit (Cohen et al., 2007). TNFα
activates the pain mediator p38 following
nerve injury, a signaling pathway which is
thought to be critical for the mediation
of pain transmission. Pre-treatment with
inhibitors of p38 (SB203580) or etaner-
cept significantly reduced mechanical allo-
dynia in rats with SNL injury (Schafers
et al., 2003). In a human clinical trial
of patients with nerve trauma, radicu-
lopathy, or carpal tunnel syndrome, the
selective p38 inhibitor dilmapimod was
shown to have a statistically significant
effect in reducing patients pain scores
(Anand et al., 2011). Conversely, a sim-
ilar p38 selective inhibitor losmapimod
did not show any significant effect in
reducing pain in a human clinical trial
of patients with peripheral focal neuro-
pathic pain related to nerve injury caused
by trauma or surgery (Ostenfeld et al.,
2013). Despite some variable clinical trial
outcomes, there is evidence to suggest that
TNFα inhibitors and next generation p38
inhibitors may prove effective in the treat-
ment of different forms of neuropathic
pain.
IL-1β INHIBITORS
Both knockout of the IL-1 receptor and
transgenic over expression of the endoge-
nous receptor antagonist IL-1RA reduced
mechanical and thermal pain hypersen-
sitivity in mice with spinal nerve injury
(Wolf et al., 2006). Similarly, a neutralizing
antibody targeting the IL-1β receptor (IL-
1R1) alleviated allodynia in mice with CCI
(Sommer et al., 1999). Therapeutics tar-
geting the IL-1 receptor such as anakinra,
a recombinant form of IL-1RA, the soluble
decoy receptor rilonacept and anti IL-1β
neutralizing antibody cannikumab, are all
currently approved for use in a number of
inflammatory diseases, including rheuma-
toid arthritis, gout, and stills diseases. A
current clinical trial is testing whether
preoperative administration of anakinra
reduces incisional pain in patients under-
going vascular or orthopedic surgical pro-
cedures by lowering the concentration
of inflammatory mediators in surgical
wounds (NCT01466764). Given the key
role of IL-1β in the development and prop-
agation of neuropathic pain in animal
models, it is noteworthy that very few trials
have been conducted testing the effects of
IL-1β inhibitors against neuropathic pain
conditions in humans.
IL-6 INHIBITORS
IL-6 is widely expressed following nerve
injury and intrathecal administration of
IL-6 results in mechanical allodynia. An
IL-6 receptor neutralizing antibody abol-
ishedmechanical allodynia associated with
spinal cord injury pain 14 days after a
single intraperitoneal injection (Guptarak
et al., 2013). The humanized IL-6 recep-
tor neutralizing antibody tocilizimab has
been approved for use in rheumatoid
arthritis and juvenile idiopathic arthri-
tis. There have also been case reports
where this antibody has been effective in
reducing pain associated with neuromyeli-
tis optica (Araki et al., 2013) and sci-
atica (Ohtori et al., 2012b). Alternative
antibodies that bind directly to IL-6
(BMS945439) are being tested in clinical
trials for the treatment of rheumatoid
arthritis. Due to the substantial evi-
dence indicating a role for IL-6 in the
propagation of neuropathic pain, ther-
apeutic antibodies targeting both the
IL-6 and its receptor may be benefi-
cial in treating certain neuropathic pain
conditions.
IL-17
Although less conspicuous than other
proinflammatory cytokines, IL-17 is a key
orchestrator of cytokine signaling in neu-
ropathic pain. IL-17 expression is signif-
icantly elevated following CCI in mice,
peaking at day 7 after injury (Kleinschnitz
et al., 2006). Knockout of IL-17 reduces
pain hypersensitivity and the activation of
CNS glia when compared to wild type
mice following partial sciatic nerve liga-
tion (PSNL), conversely injection of IL-
17 results in increased mechanical and
thermal hypersensitivity and neutrophil
migration to the site of injection (Kim
and Moalem-Taylor, 2011). IL-17 medi-
ated hyperalgesia has been shown to be
dependent on TNFα/TNFRA1 signaling
(McNamee et al., 2011). Intraperitoneal
injection of amonoclonal antibody against
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IL-17 into rats with antigen induced
arthritis reduced paw guarding and hyper-
algesia (Richter et al., 2012). Humanized
monoclonal antibodies against IL-17, such
as secukinumab, are now being assessed
for efficacy in treating a range of inflam-
matory conditions including psoriasis and
rheumatoid arthritis, and based on results
with animal models these biologics could
be tested in human clinical trials for treat-
ment of neuropathic pain.
THERAPEUTICS AIMED AT RESOLVING
INFLAMMATION
As an alternative to targeting proin-
flammatory cytokines, another treatment
option is to promote resolution of the
inflammation by stimulating the expres-
sion of anti-inflammatory cytokines. A
perceived advantage of this strategy is that
it does not directly inhibit the activity of
proinflammatory cytokines, which may be
required for processes such as Wallerian
degeneration and peripheral axonal regen-
eration.
ANTI-INFLAMMATORY CYTOKINES
A single dose of IL-10 had long-lasting
behavioral effects in rats with excito-
toxic spinal cord injury (Plunkett et al.,
2001). Intrathecal gene therapy targeting
the expression of IL-10 has been shown to
be efficacious; delivery of adeno-associated
viral IL-10 transiently reversed allodynia
(Milligan et al., 2005), whilst repeated
delivery of naked DNA encoding IL-10
reversed allodynia for up to 2 months after
CCI (Milligan et al., 2006). Administration
of IL-4 inhibited the production of TNFα
and IL-1β in hyperalgesia models (Cunha
et al., 1999) and intraneural injection of
TGFβ caused a delayed and reduced pain
hypersensitivity in rats with PSNL. This
attenuated the homing of cytokine pro-
ducing MAC+ macrophages and reduced
the infiltration of T cells into the injured
nerve (Echeverry et al., 2013). Data on the
effectiveness of anti-inflammatory ther-
apies in treating neuropathic pain in
humans is limited, and has to date focused
largely on IL-10. Recombinant human IL-
10 (such as Ilodecakin/Tenovil) has been
tested with variable success in treating
chronic inflammatory conditions such as
psoriasis, Crohn’s disease, and rheumatoid
arthritis. To the best of our knowledge,
human trials investigating the efficacy of
similar therapies in treating neuropathic
pain are yet to be conducted.
SUMMARY AND PERSPECTIVE
The remarkable success of targeted inhi-
bition of several cytokines, such as TNFα,
in patients with rheumatoid arthritis,
psoriasis and many other diseases has
fundamentally revised the treatment of
chronic inflammatory diseases. This sug-
gests that different conditions may share
common pathophysiology and may ben-
efit from disruption of the cytokine net-
work. Indeed, several neuropathic pain
conditions have been shown to have dys-
regulation of cytokines, and the use of
biologics targeting cytokines is an exciting
and promising strategy in the quest to find
more effective treatments for neuropathic
pain. There are two basic sub-strategies
that can be followed: (1) to target certain
proinflammatory cytokines or their recep-
tors to inhibit their activity, (2) to enhance
the resolution of inflammation by pro-
moting the activity of anti-inflammatory
cytokines. The few clinical trials that have
tested the efficacy of cytokine inhibitors
in chronic neuropathic pain so far have
demonstrated mixed results, suggesting
that human validation studies will be nec-
essary to identify the appropriate cytokines
for a given neuropathic pain syndrome. It
is anticipated that new effective cytokine
targets will be discovered and will allow
future novel treatment strategies for neu-
ropathic pain.
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